| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-03-24 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.030 | -0.020 | 0.0100 | ||||
| REV | 8.780M | 9.531M | 751.000K |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: Pro-Dex (NASDAQ:PDEX), LENSAR (NASDAQ:LNSR), Second Sight Medical (NASDAQ:EYES), Bluejay Diagnostics (NASDAQ:BJDX) and Talis Biomedical (NASDAQ:TLIS).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Maxim Group on October 14, 2020. The analyst firm set a price target for 1.00 expecting BIOL to rise to within 12 months (a possible 194.12% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $0.34 last updated Fri Jan 21 2022 21:00:03 GMT+0000 (Coordinated Universal Time).
A quarterly cash dividend of $0.00 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s $Q4 earnings are confirmed for after-market on March 24, 2022.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.